Related Experiment Video
Updated: Dec 28, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Preneoplastic changes persist after IGF-IR downregulation and tumor regression
R A Jones1, J J Petrik, R A Moorehead
1Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
Targeting the type I insulin-like growth factor receptor (IGF-IR) can regress mammary tumors. However, IGF-IR targeting agents do not eradicate all tumor cells, allowing for rapid tumor re-emergence.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- The type I insulin-like growth factor receptor (IGF-IR) plays a role in tumorigenesis.
- IGF-IR targeting agents are in clinical trials for cancer treatment.
- Previous studies showed IGF-IR downregulation causes mammary tumor regression in mice.
Purpose of the Study:
- To examine mammary tissue in mice with stably regressed tumors after IGF-IR downregulation.
- To investigate the potential for tumor recurrence upon IGF-IR re-expression.
Main Methods:
- Examined mammary tissue from mice with regressed tumors after IGF-IR transgene downregulation.
- Re-expressed the IGF-IR transgene in mammary tissue with regressed tumors.
- Observed tumor re-emergence and characteristics of regressed lesions.
Main Results:
- Regressed lesions contained cell debris and doxycycline crystals.
- Three mice showed significant lobuloalveolar development.
- Re-expression of IGF-IR led to rapid mammary tumor re-emergence, some from regressed areas.
Conclusions:
- IGF-IR targeting agents can regress mammary tumors but do not eradicate all cells.
- Preneoplastic lesions persist after regression.
- Tumors rapidly re-appear upon IGF-IR re-expression, indicating incomplete treatment efficacy.
More Related Videos
07:36Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
Published on: June 12, 2021
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mitogens and the Cell Cycle
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...